vs
Side-by-side financial comparison of CSW INDUSTRIALS, INC. (CSW) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
CSW INDUSTRIALS, INC. is the larger business by last-quarter revenue ($233.0M vs $196.9M, roughly 1.2× Pacira BioSciences, Inc.). On growth, CSW INDUSTRIALS, INC. posted the faster year-over-year revenue change (20.3% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $22.7M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 5.1%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CSW vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $233.0M | $196.9M |
| Net Profit | $10.3M | — |
| Gross Margin | 39.7% | 79.5% |
| Operating Margin | 7.4% | 1.2% |
| Net Margin | 4.4% | — |
| Revenue YoY | 20.3% | 5.1% |
| Net Profit YoY | -61.9% | — |
| EPS (diluted) | $0.62 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $233.0M | $196.9M | ||
| Q3 25 | $277.0M | $179.5M | ||
| Q2 25 | $263.6M | $181.1M | ||
| Q1 25 | $230.5M | $168.9M | ||
| Q4 24 | $193.6M | $187.3M | ||
| Q3 24 | $227.9M | $168.6M | ||
| Q2 24 | $226.2M | $178.0M | ||
| Q1 24 | $210.9M | $167.1M |
| Q4 25 | $10.3M | — | ||
| Q3 25 | $40.7M | $5.4M | ||
| Q2 25 | $40.9M | $-4.8M | ||
| Q1 25 | $35.1M | $4.8M | ||
| Q4 24 | $26.9M | — | ||
| Q3 24 | $36.1M | $-143.5M | ||
| Q2 24 | $38.6M | $18.9M | ||
| Q1 24 | $31.8M | $9.0M |
| Q4 25 | 39.7% | 79.5% | ||
| Q3 25 | 43.0% | 80.9% | ||
| Q2 25 | 43.8% | 77.4% | ||
| Q1 25 | 44.2% | 79.7% | ||
| Q4 24 | 41.4% | 78.7% | ||
| Q3 24 | 45.6% | 76.9% | ||
| Q2 24 | 47.5% | 75.1% | ||
| Q1 24 | 44.4% | 71.6% |
| Q4 25 | 7.4% | 1.2% | ||
| Q3 25 | 20.5% | 3.5% | ||
| Q2 25 | 20.8% | 4.7% | ||
| Q1 25 | 19.5% | 1.2% | ||
| Q4 24 | 15.3% | 13.2% | ||
| Q3 24 | 22.6% | -82.8% | ||
| Q2 24 | 24.3% | 15.9% | ||
| Q1 24 | 21.0% | 7.9% |
| Q4 25 | 4.4% | — | ||
| Q3 25 | 14.7% | 3.0% | ||
| Q2 25 | 15.5% | -2.7% | ||
| Q1 25 | 15.2% | 2.8% | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | 15.8% | -85.1% | ||
| Q2 24 | 17.1% | 10.6% | ||
| Q1 24 | 15.1% | 5.4% |
| Q4 25 | $0.62 | $0.05 | ||
| Q3 25 | $2.41 | $0.12 | ||
| Q2 25 | $2.43 | $-0.11 | ||
| Q1 25 | $2.05 | $0.10 | ||
| Q4 24 | $1.60 | $0.38 | ||
| Q3 24 | $2.26 | $-3.11 | ||
| Q2 24 | $2.47 | $0.39 | ||
| Q1 24 | $2.03 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.2M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $1.1B | $693.1M |
| Total Assets | $2.3B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.2M | $238.4M | ||
| Q3 25 | $31.5M | $246.3M | ||
| Q2 25 | $38.0M | $445.9M | ||
| Q1 25 | $225.8M | $493.6M | ||
| Q4 24 | $213.8M | $484.6M | ||
| Q3 24 | $273.2M | $453.8M | ||
| Q2 24 | $18.9M | $404.2M | ||
| Q1 24 | $22.2M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | $800.1M | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
| Q4 25 | $1.1B | $693.1M | ||
| Q3 25 | $1.1B | $727.2M | ||
| Q2 25 | $1.1B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.0B | $778.3M | ||
| Q3 24 | $1.0B | $749.6M | ||
| Q2 24 | $650.2M | $879.3M | ||
| Q1 24 | $615.7M | $892.2M |
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.4B | $1.6B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.0B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | 0.75× | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $43.7M |
| Free Cash FlowOCF − Capex | $22.7M | $43.5M |
| FCF MarginFCF / Revenue | 9.8% | 22.1% |
| Capex IntensityCapex / Revenue | 2.6% | 0.1% |
| Cash ConversionOCF / Net Profit | 2.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | $162.0M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.9M | $43.7M | ||
| Q3 25 | $61.8M | $60.8M | ||
| Q2 25 | $60.6M | $12.0M | ||
| Q1 25 | $27.3M | $35.5M | ||
| Q4 24 | $11.6M | $33.1M | ||
| Q3 24 | $66.8M | $53.9M | ||
| Q2 24 | $62.7M | $53.2M | ||
| Q1 24 | $22.4M | $49.1M |
| Q4 25 | $22.7M | $43.5M | ||
| Q3 25 | $58.7M | $57.0M | ||
| Q2 25 | $57.7M | $9.3M | ||
| Q1 25 | $22.8M | $26.9M | ||
| Q4 24 | $8.5M | $31.0M | ||
| Q3 24 | $61.3M | $49.8M | ||
| Q2 24 | $59.6M | $51.6M | ||
| Q1 24 | $17.5M | $46.3M |
| Q4 25 | 9.8% | 22.1% | ||
| Q3 25 | 21.2% | 31.7% | ||
| Q2 25 | 21.9% | 5.1% | ||
| Q1 25 | 9.9% | 15.9% | ||
| Q4 24 | 4.4% | 16.6% | ||
| Q3 24 | 26.9% | 29.6% | ||
| Q2 24 | 26.3% | 29.0% | ||
| Q1 24 | 8.3% | 27.7% |
| Q4 25 | 2.6% | 0.1% | ||
| Q3 25 | 1.1% | 2.2% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 2.0% | 5.1% | ||
| Q4 24 | 1.6% | 1.1% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 1.4% | 0.9% | ||
| Q1 24 | 2.3% | 1.7% |
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | 11.20× | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | 7.37× | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.62× | 2.82× | ||
| Q1 24 | 0.71× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
